Bausch Health Companies Inc. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
Bausch Health Companies Inc. (BHC) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $3.00 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2024-10-31
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for the quarter ending 2023-03-31 was $6.00M.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for the quarter ending 2021-03-31 was -$6.00M.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for the quarter ending 2020-03-31 was -$5.00M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 3 month | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 6 month | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 9 month |
|---|---|---|---|
| 2024-09-30 | $3.00M 10-Q · filed 2024-10-31 | ||
| 2023-09-30 | $7.00M 10-Q · filed 2024-10-31 | ||
| 2023-06-30 | $7.00M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $6.00M 10-Q · filed 2024-05-02 | ||
| 2022-09-30 | $5.00M 10-Q · filed 2023-11-02 | ||
| 2021-09-30 | -$8.00M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$7.00M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | -$6.00M 10-Q · filed 2022-05-10 | ||
| 2020-09-30 | -$7.00M 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | -$4.00M 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | -$5.00M 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |